Business
Reviva Pharmaceuticals to Present at Three Upcoming Scientific Conferences in May 2023
CUPERTINO, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage
About this update from Reviva Pharmaceuticals Holdings, Inc.
[{"type":"text","content":"CUPERTINO, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), respiratory and metabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will be presenting at three upcoming scientific conferences to be held in May 2023. Details for the conferences can be found below: International Societies for Investigative Dermatology (ISID) Meeting 2023Brilaroxazine topical liposomal-gel formulation displays efficacy in the imiquimod-induced psoriatic BALB/c mouse modelDate: May 12, 2023Time: 6:10 – 7:40pm JSTPresenters: Laxminarayan BhatLocation: Keio Plaza Hotel, Tokyo, Japan American Society for Pharmacology and Experimental Therapeutics (ASPET) 2023Poster Presentation: CYP3A inhibition and induction exert limited effects on brilaroxazine pharmacokineticDate: Friday, May 19, 2023Time: 5:00-7:00pm ETPresenters: Laxminarayan Bhat Location: St. Louis Union Station Hotel, St. Louis, MA, USA Poster Presentation: Single-dose Brilaroxazine Pharmacokinetics, Metabolism, and Excretion Profile in Animals and HumansDate: Saturday, May 20, 2023 Time: 5:00-7:00pm ETPresenters: Laxminarayan BhatLocation: St. Louis Union Station Hotel, St. Louis, MA, USA American Thoracic Society (ATS) 2023Poster Presentation: Brilaroxazine Efficacy in a Bleomycin-induced Rodent Model of Idiopathic Pulmonary FibrosisDate: Wednesday, May 24, 2023Time: 8:00-10:00am ETPresenters: Laxminarayan BhatLocation: Walter E. Washington Convention Center, Washington, DC, USA About Reviva’s Lead Drug Candidate Brilaroxazine Brilaroxazine is a new chemical entity with potent affinity and selectivity against key serotonin and dopamine receptors implicated in schizophrenia and its comorbid symptoms. In a multinational, multicenter, double-blind Phase 2 study in 234 patients with acute schizophrenia or schizoaffective disorder, brilaroxazine met its primary endpoint, reducing Positive and Negative Syndrome Scale (PANSS) total score and demonstrating statistically significant improvement of overall drug treatment outcomes using Clinical Global Impression (CGI) scale and for secondary endpoints evaluating social functioning, and...